ARTICLE | Clinical News
Rhône-Poulenc Rorer Inc. regulatory update
June 5, 1995 7:00 AM UTC
Rhône-Poulenc Rorer Inc. RPR asked the FDA to remove Taxotere (docetaxel), RPR's anticancer agent, from the agenda of the Oncologic Drugs Advisory Committee (ODAC) scheduled for June 8. RPR (College...